HER-2 Negative Breast Cancer Market

1
Global HER-2 Negative Breast Cancer Market Is
Estimated To Witness High Growth Owing To
Increasing Awareness and Advancements in
Treatment Options
The global HER-2 Negative Breast Cancer market
is estimated to be valued at US12,647.0 Mn in
2022 and is expected to exhibit a CAGR of 10.1
over the forecast period (2023-2030), as
highlighted in a new report published by
Coherent Market Insights. Market Overview
HER-2 Negative Breast Cancer is a type of breast
cancer that does not express the HER-2 protein,
which is responsible for promoting the growth of
cancer cells. The market offers various treatment
options, including chemotherapy, hormone
therapy, targeted therapy, and immunotherapy.
These therapies aim to inhibit the growth and
spread of cancer cells, improving patient
outcomes and survival rates. Increasing
awareness about breast cancer and advancements in
treatment options are driving the growth of the
HER-2 Negative Breast Cancer market. Market
Dynamics 1. Driver Increasing Awareness With
the growing prevalence of breast cancer globally,
there has been a significant increase in
awareness campaigns and initiatives. Government
organizations, non-profits, and healthcare
providers are actively spreading awareness
regarding breast cancer, its early detection, and
treatment options. This increased awareness has
resulted in a higher number of patients seeking
timely diagnosis and treatment. 2. Driver
Advancements in Treatment Options There have
been significant advancements in the treatment
options available for HER-2 Negative Breast
Cancer. Targeted therapies, such as HER-2
inhibitors and PARP inhibitors, have shown
promising results in inhibiting the growth of
cancer cells. Additionally, immunotherapies, such
as PD-1 inhibitors, have shown efficacy in
improving survival rates. These advancements have
fueled the demand for novel treatment options
among patients. SWOT Analysis Strengths 1.
Targeted Therapies Availability of targeted
therapies that specifically inhibit the growth of
cancer cells. 2. Awareness Campaigns
Increasing awareness campaigns promoting early
detection and treatment of breast cancer.
Weaknesses 1. High Cost of Treatment The cost
associated with advanced treatment options can be
a barrier for
2
patients in low-income regions. 2. Limited
Access to Healthcare Lack of access to
healthcare facilities and specialized treatment
centers in certain regions. Opportunities 1.
Emerging Markets Untapped potential in emerging
markets with a growing patient population and
increasing healthcare infrastructure. 2.
Personalized Medicine Integration of
personalized medicine approaches for improved
treatment outcomes. Threats 1. Stringent
Regulatory Requirements Increasing regulatory
requirements for the approval of novel treatment
options. 2. Competition from Biosimilars The
entry of biosimilar products in the market,
leading to price erosion for branded therapies.
Key Takeaways 1 The global HER-2 Negative
Breast Cancer market is expected to witness high
growth, exhibiting a CAGR of 10.1 over the
forecast period. This growth can be attributed to
the increasing awareness about breast cancer,
leading to early detection and treatment
initiation. 2 Geographically, North America is
expected to dominate the HER-2 Negative Breast
Cancer market due to the presence of advanced
healthcare infrastructure and high awareness
levels. However, Asia Pacific is anticipated to
witness the fastest growth due to the rising
prevalence of breast cancer and increasing
investments in healthcare. 3 Key players
operating in the global HER-2 Negative Breast
Cancer market include Pfizer Inc., Novartis AG,
Merck Co. Inc., GSK PLC, AstraZeneca, Eli Lilly
and Company, and Bristol-Myers Squibb Company
(Celgene Corporation), among others. These
companies are actively investing in research and
development activities to introduce innovative
treatment options and strengthen their market
presence. In conclusion, the global HER-2
Negative Breast Cancer market is expected to
witness significant growth due to increasing
awareness and advancements in treatment options.
However, challenges such as high treatment costs
and limited access to healthcare need to be
addressed to ensure equitable access to quality
care for all patients.